iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
CAT No: R1458
CAS No: 1392278-76-0
Synonyms/Alias: iRGD peptide;c(CRGDKGPDC);1392278-76-0;UNII-Z8MXU5GH4Q;iRGD;(6S,9S,15S,18R,23R,26S,29S)-18-amino-6-(4-aminobutyl)-9,26-bis(carboxymethyl)-15-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontane-23-carboxylic acid;CEND-1;iRGD-peptide;2,2'-((3S,6R,11R,14S,20S,23S,31aS)-11-amino-23-(4-aminobutyl)-6-carboxy-14-(3-guanidinopropyl)-1,4,12,15,18,21,24,27-octaoxooctacosahydro-1H-pyrrolo[2,1-j][1,2]dithia[5,8,11,14,17,20,23,26]octaazacyclononacosine-3,20-diyl)diacetic acid;Z8MXU5GH4Q;NSC838763;NSC-838763;DA-64499;G16330;Internalized-arginylglycylaspartic acid cyclic peptide;Q48988348;(3S,6R,11R,14S,20S,23S,31aS)-11-amino-23-(4-aminobutyl)-14-(3-carbamimidamidopropyl)-3,20-bis(carboxymethyl)-1,4,12,15,18,21,24,27-octaoxo-icosahydro-2H-pyrrolo[2,1-j]1,2-dithia-5,8,11,14,17,20,23,26-octaazacyclononacosane-6-carboxylic acid;L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C35H57N13O14S2 |
M.W/Mr. | 948 |
Sequence | One Letter Code:CRGDKGPDC Three Letter Code:H-Cys(1)-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys(1)-OH |
Application | iRGD peptides have been shown to increase the accumulation and penetration of anticancer drugs in tumors, but not into normal tissues-regardless of whether the drug is coupled to or administered with the peptide. |
Purity | 98% |
Long-term Storage Conditions | H2O : ≥ 50 mg/mL (52.74 mM) |
Shipping Condition | Room temperature in continental US; may vary elsewhere. |
InChI | InChI=1S/C35H57N13O14S2/c36-8-2-1-5-18-30(57)42-14-25(50)48-10-4-7-23(48)33(60)46-21(12-27(53)54)32(59)47-22(34(61)62)16-64-63-15-17(37)28(55)44-19(6-3-9-40-35(38)39)29(56)41-13-24(49)43-20(11-26(51)52)31(58)45-18/h17-23H,1-16,36-37H2,(H,41,56)(H,42,57)(H,43,49)(H,44,55)(H,45,58)(H,46,60)(H,47,59)(H,51,52)(H,53,54)(H,61,62)(H4,38,39,40)/t17-,18-,19-,20-,21-,22-,23-/m0/s1 |
InChI Key | YHTTWXCDIRTOQX-FQJIPJFPSA-N |
Canonical SMILES | O=C1[C@@]2([H])N(C(CNC([C@@H](NC([C@](NC(CNC([C@@](CCCNC(N)=N)([H])NC([C@@H](N)CSSC[C@@H](C(O)=O)NC([C@H](CC(O)=O)N1)=O)=O)= O)=O)([H])CC(O)=O)=O)CCCCN)=O)=O)CCC2 |
1. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
2. Cationic cell-penetrating peptides are potent furin inhibitors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.